1	Rapid Method Communication
2	
3	Preliminary optimisation of simplified sample preparation method to permit
4	direct detection of SARS-CoV-2 within saliva samples using reverse-
5	transcription loop-mediated isothermal amplification (RT-I AMP)
6	
7	*Emma L & Howson ^{1,2} *Stenhen P Kidd ³⁺ Jason Sawyer ⁴ Claire Cassar ⁴ David Cross ⁴ Tom Lewis ⁴
, 8	Jess Hockev ⁴ . Samantha Rivers ⁴ . Saira Cawthraw ⁴ . Ashley Banvard ⁴ . Michael Andreou ⁵ . Nick Morant ¹ .
9	Duncan Clark ¹ , Charlotte Walsh ¹ , Shailen Laxman ⁵ , Rebecca Houghton ³ , Joanne Slater-Jefferies ⁶ , Paula
10	Costello ⁷ , Ian Brown ⁴ , Nicholas Cortes ^{3,8} , Keith M. Godfrey ^{7,9} , ⁺ Veronica L. Fowler ³
11	
12	¹ GeneSys Biotech Limited, Camberley, Surrey, UK
13	² The Pirbright Institute, Ash Road, Woking, Surrey, UK
14	³ Hampshire Hospitals NHS Foundation Trust, Department of Microbiology, Basingstoke and
15	Winchester, UK
16	⁵ Animal and Plant Health Agency, New Haw, Addlestone, Surrey, UK
17 10	⁶ National Riofilms Innovation Centre, University of Southampton, UK
10 19	⁷ MRC Lifecourse Enidemiology Unit University of Southampton, UK
20	⁸ Gibraltar Health Authority, Gibraltar, UK
21	⁹ NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital
22	Southampton, UK
23	
24	Corresponding author: E-mail: stephen.kidd@hhft.nhs.uk
25	
26	*Joint first authors
27	
28	Running title
29	RT-LAMP assay for the rapid detection of SARS-CoV-2 in saliva.
30	
31	Keywords
.	CARS COV/2 COV/ID 10 DT LAMP ranid diagnostics near nations testing direct detection
32	SARS-COV-2, COVID-19, RT-LAMP, rapid diagnostics, near patient testing, direct detection
22	
34	
35	

36 Abstract

37 We describe the optimization of a simplified sample preparation method which permits rapid and 38 direct detection of SARS-CoV-2 RNA within saliva using reverse-transcription loop-mediated 39 isothermal amplification (RT-LAMP). Treatment of saliva samples prior to RT-LAMP by dilution 1:1 in 40 Mucolyse[™], followed by dilution (within the range of 1:5 to 1:40) in 10% (w/v) Chelex[®] 100 Resin and 41 a 98°C heat step for 2 minutes enabled detection of SARS-CoV-2 RNA in all positive saliva samples 42 tested, with no amplification detected in pooled negative saliva. The time to positivity for which SARS-43 CoV-2 RNA was detected in these positive saliva samples was proportional to the real-time reverse-44 transcriptase PCR cycle threshold (C_T), with SARS-CoV-2 RNA detected in as little as 05:43 (C_T 21.08), 45 07:59 (C_T 24.47) and 08:35 (C_T 25.27) minutes, respectively. The highest C_T where direct RT-LAMP 46 detected SARS-CoV-2 RNA was 31.39 corresponding to a 1:40 dilution of a positive saliva sample with 47 a starting C_T of 25.27. When RT-LAMP was performed on pools of SARS-CoV-2 negative saliva samples 48 spiked with whole inactivated SARS-CoV-2 virus, RNA was detected at dilutions spanning 1:5 to 1:160 representing C_T's spanning 22.49-26.43. Here we describe a simple but critical rapid sample 49 50 preparation method which can be used up front of RT-LAMP to permit direct detection of SARS-CoV-51 2 within saliva samples. Saliva is a sample which can be collected non-invasively without the use of 52 highly skilled staff and critically can be obtained from both health care and home settings. Critically, 53 this approach overcomes both the requirement and validation of different swabs and the global 54 bottleneck observed in obtaining RNA extraction robots and reagents to enable molecular testing by 55 PCR. Such testing opens the possibility of public health approaches for effective intervention to control 56 the COVID-19 pandemic through regular SARS-CoV-2 testing at a population scale, combined with 57 isolation and contact tracing for positive cases.

58

60 Introduction

61 The COVID-19 pandemic caused by the SARS-CoV-2 virus poses a profound global threat to 62 communities, economic activity and healthcare systems. It is generally accepted that a safe and efficacious vaccine will not be widely available in the immediate future whilst uncertainty remains 63 64 over the trajectory of the pandemic. Moreover, herd immunity from a high proportion of the 65 population having become immune to SARS-CoV-2 is not thought to be a viable public health strategy 66 by most observers. One public health approach that has been advocated for suppression of the COVID-67 19 pandemic is regular SARS-CoV-2 testing at a population scale, combined with isolation and contact 68 tracing for positive cases¹. Such an approach requires a rapid relatively inexpensive diagnostic test for 69 the presence of the SARS-CoV-2 virus, ideally based on samples that can be simply collected in both 70 health care and non-health care (e.g. home) settings².

71

72 The current international gold standard for diagnosis of infection with SARS-CoV-2 is detection of viral 73 RNA by real-time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCR) from a naso-pharyngeal 74 or oropharyngeal swab in viral transport medium³. However, the procedure for collecting a good 75 quality sample using this approach requires a degree of training and skill, potentially exposes the 76 sampler to infectious droplets, and can be uncomfortable and traumatic for the patient, especially if 77 undertaken frequently. Critically, supply issues during the pandemic have led to bottlenecks in the 78 availability of reagents for molecular assays, leading to demand for bespoke extraction kits far 79 outweighing available supply and hampering testing efforts globally. Alongside this, the requirement 80 for swab testing has led to key manufacturers being unable to cope with swab demand for patient 81 sampling^{4,5}. This has meant that laboratories have had to undertake frequent and time-consuming 82 assay validation on different swab types. As such, exploring alternative sample types and RNA 83 detection methods that circumvent the issues above is an attractive solution.

Saliva is a sample which shows promise for infection diagnostics, including for diagnostic detection of
coronaviruses and has been shown as a site where SARS-CoV-2 is found in early infection^{6,7}. Collection
of saliva is straightforward and can be done by the patient themselves using a drooling technique, and
collection devices include a simple, widely available, universal plastic container.

89

90 Reverse-Transcription Loop-mediated isothermal AMPlification (RT-LAMP) is a highly sensitive 91 reverse-transcription, autocycling, isothermal, strand displacement nucleic acid amplification 92 technology⁸ which is more resistant to inhibitors than rRT-PCR), enabling simplification and even removal of the extraction procedure⁹⁻¹¹. LAMP technologies have been applied for the detection of a 93 wide range of pathogens^{12–14} including positive-sense RNA viruses¹⁰ and has been used extensively in 94 the veterinary^{15,16} and plant industry^{17–19} and more recently as a human diagnostic^{12,20,21}. At the height 95 96 of the SARS-CoV-2 epidemic in the UK in early 2020, Hampshire Hospitals NHS Foundation Trust (HHFT) 97 validated a novel RT-LAMP assay for the detection of SARS-CoV-2 RNA within nasopharyngeal and oropharyngeal swabs either directly from swab, or following RNA extraction²². For direct detection of 98 99 SARS-CoV-2 RNA from swab, a simple dilution of 1:20 of the viral transport media in nuclease free 100 water (NFW) was shown to be sufficient to overcome inhibition and to achieve sensitivity (DSe) and 101 specificity (DSp) of 67% and 97%, respectively. When setting rRT-PCR cycle threshold (C_T) cut-offs of 102 \leq 33 and \leq 25, the DSe increased to 75% and 100%, respectively, with the specificity retained. Within 103 this first study²², preliminary evaluation of Direct RT-LAMP for detection of SARS-CoV-2 in other clinical 104 samples was performed using fourteen saliva samples collected from hospital in-patients confirmed 105 from paired swabs as positive and negative for SARS-CoV-2. Using a 1:20 dilution of saliva in NFW, 106 SARS-CoV-2 RNA was detected as expected in four of the positive swab samples but was unexpectedly 107 detected in only two of the saliva samples. This indicated that more work was required to optimize 108 the crude sample preparation method for detection of SARS-CoV-2 in saliva. Herein we describe the 109 further optimisation of a simple sample preparation method to permit direct detection of SARS-CoV-110 2 within saliva samples using Direct RT-LAMP.

111

114

112 Materials and Methods

113 Virus isolates and clinical specimens

115 Optimisation of Direct RT-LAMP for detection of SARS-CoV-2 RNA in saliva was performed using three 116 SARS-CoV-2 positive saliva samples collected from symptomatic patients at Hampshire Hospitals NHS 117 Foundation Trust (HHFT) (n=1) and University Hospital Southampton (UHS) (n=2) who had previously 118 had rRT-PCR positive SARS-CoV-2 positive naso-pharyngeal samples. An additional 15 SARS-CoV-2 119 negative saliva samples collected from asymptomatic UHS healthcare staff were used to prepare a 120 pooled sample for specificity analysis. For spiking experiments, one pool of 25 SARS-CoV-2 negative 121 saliva samples from asymptomatic UHS staff, and a second pool of 5 SARS-CoV-2 negative saliva 122 samples also from asymptomatic UHS staff, were used to prepare pooled samples for spiking with 123 whole inactivated virus (SARS-CoV-2 at ~1x10⁵TCID₅₀/ml was inactivated using beta-propriolactone 124 (BPL). Collection of saliva involved the patient providing a fresh saliva sample into a 10ml universal container. Each positive saliva sample was diluted 1:1 in Mucolyse[™] (active ingredient: dithiothreitol, 125 126 Pro-Lab Diagnostics, UK) prior to dilution in either NFW or 10% Chelex® 100 Resin (Bio-Rad 127 Laboratories, Watford, UK)²³. Mucolyse[™] was also added 1:1 to the final pool of negative saliva 128 samples and the SARS-CoV-2 spiked pools.

129

130 **RNA extraction**

The saliva sample collected within the HHFT was extracted using the Maxwell® RSC Viral Total Nucleic
Acid Purification Kit (Promega UK Ltd., Southampton, UK) according to manufacturer's instructions.
Briefly, 200 µl of sample was added to 223 µl of prepared lysis solution (including 5 µl per reaction of
Genesig® Easy RNA Internal extraction control, Primerdesign Ltd, Chandler's Ford, UK). Samples were
then inactivated for 10 minutes at room temperature within the safety cabinet and 10 minutes at 56°C
on a heat block before automated RNA extraction using a Maxwell® RSC 48 Instrument (Promega UK
Ltd., Southampton, UK). RNA was eluted in 50 µl of NFW.

138

The saliva samples collected from UHS were extracted using the MagMAX[™]CORE Nucleic acid purification kit (Thermofisher). Briefly, 10µl of sample (diluted in 190µl DEPC treated water) was added to 700µl of prepared lysis solution. Samples were then inactivated for 10 minutes at room temperature within the safety cabinet before automated RNA extraction using a KingfisherFlex (Thermofisher). RNA was eluted in 90 µl of NFW.

144

145 *Real-time reverse-transcription PCR (rRT-PCR)*

146 All rRT-PCR assays were performed in single replicates using 5 μ l of RNA template. The saliva sample 147 collected within the HHFT was analysed using the COVID-19 genesig® Real-Time PCR assay 148 (Primerdesign Ltd, Chandler's Ford, UK) according to the manufacturer's guidelines, on a MIC qPCR 149 Cycler (Bio Molecular Systems, London, UK). The cycling conditions were adjusted to the following: a 150 reverse-transcription (RT) step of 10 minutes at 55°C, a hot-start step of 2 minutes at 95°C, and then 151 45 cycles of 95°C for 10 seconds and 60°C for 30 seconds. The Genesig® COVID-19 positive control 152 included in the kit, a negative extraction control, and a no template control were also included on 153 each rRT-PCR run.

154

155 The saliva samples collected from the UHS and the spiked whole virus dilution series were tested using 156 the E gene RT-PCR as described previously (Corman et al., 2020) using the AgPath-ID[™] PCR kit 157 (Thermofisher). Samples were run on an Aria qPCR Cycler (Agilent) and results analysed using the 158 Agilent AriaMX 1.5 software. The cycling conditions were adjusted to the following: a reverse-159 transcription (RT) step of 10 minutes at 55X°C, a hot-start step of 3 minutes at 94°C, and then 45 cycles 160 of 94°C for 15 seconds and 60°C for 15-30 seconds during data acquisition. The SARS-CoV2 positive control RNA, a negative extraction control, and a no template control were also included on each rRT-161 PCR run. 162

164

165 Preparation of 10% (w/v) Chelex[®] 100 Resin

10% (w/v) Chelex[®] 100 Resin was made up by resuspending Chelex[®] 100 Resin (200-400 mesh) (BioRad Laboratories, catalogue number #142-1253) in Milli-Q[®] water at 10% (w/v). The solution was
heated at 70°C for 30 minutes. Two washes in Milli-Q[®] water were performed by allowing the Chelex[®]
100 Resin to settle, removing the supernatant, adding Milli-Q[®] water to 10% (w/v) and shaking. After

a second wash, Milli-Q[®] water was added to give a final 10% Chelex[®] 100 (w/v) Resin solution.

171

172 **Reverse-transcription loop-mediated isothermal amplification (RT-LAMP)**

173 RT-LAMP reactions were performed using OptiGene Ltd. (Camberley, UK) COVID-19_Direct RT-LAMP

174 KIT-500 kit which targets the *ORF1ab* region of the SARS-CoV-2 genome.

175

176 Each RT-LAMP reaction consisted of: 17.5 µl of RT-LAMP Isothermal Mastermix (containing 8 units of 177 GspSSD2.0 DNA Polymerase, 7.5 units of Opti-RT reverse transcriptase and a proprietary fluorescent 178 dsDNA intercalating dye and a proprietary enhancing enzyme), 2.5 µl of 10X COVID-19 Primer Mix, 179 and 5 µl of RNA/sample. RT-LAMP reactions were performed in duplicate at 65°C for 20 mins on a 180 Genie[®] HT (OptiGene Ltd., UK). An exponential increase in fluorescence (ΔF) indicated a positive 181 reaction, which was quantified by a time to positivity (Tp) value, called at the point where the 182 fluorescence level on the amplification curve, crosses the threshold of 5000. To confirm the specificity 183 of the amplification reaction, an anneal curve was performed: RT-LAMP products were heated to 98°C 184 for 1 min, then cooled to 80°C decreasing the temperature by 0.05°C/s.

185

Genie[®] embedded software (OptiGene Ltd., UK) was utilised to analyse RT-LAMP results and define thresholds for result calling. All RT-LAMP reactions were performed in duplicate, and a sample was considered positive when a Tp was observed in at least one replicate with amplification above 5000

fluorescence points and had an anneal temperature of between 81.50°C and 84.05°C with a derivative
above 2500 F/°C.

191

For Direct RT-LAMP, 5 μl of saliva diluted in NFW or 10% (w/v) Chelex[®] 100 Resin (Bio-rad) spanning 1 192 193 in 5 to 1 in 640, with and without heat treatment (70°C for 4 minutes or 98°C for 2 mins) was added 194 to the reaction. Heating was performed on a dry heat block. The same treatments were applied to the 195 saliva pools spiked with whole inactivated virus and to the non-spiked negative saliva pool, however 196 the first spiked saliva pool was only titrated as far as 1:40 in the first instance. After addition to direct 197 RT-LAMP all treatments were pooled according to dilution (e.g. all temperature treatments were 198 pooled according to the dilution) and extracted for rRT-PCR analysis. 199 Results 200

201 Optimisation of the Direct-RT-LAMP

202 Optimization of the Direct RT-LAMP assay for detection of SARS-CoV-2 was determined using three

203 positive saliva samples, a pool of non-spiked negative saliva and a pool of spiked saliva.

The three positive saliva samples diluted 1:1 in Mucolyse[™] rRT-PCR C_T values were 21.08, 24.47 and

205 25.27 (Table 1). For the first spiked saliva pool, the whole inactivated virus spiked into saliva prior to

206	dilution rRT-PCR C_T was 26.70 (Table 2). For the second spiked saliva pool, the whole inactivated virus
207	spiked into saliva diluted 1:1 in Mucolyse [™] (prior to further dilutions) rRT-PCR C _T was 22.86 (Table 3).
208	

From rRT-PCR data samples were assessed for sensitivity using the Direct-LAMP protocol. Samples were assessed in order of highest viral load by rRT-PCR (C_T 21.08: Table 1, Panel A) result to lowest (C_T 25.27: Table 1, Panel C).

212

The saliva sample with the highest viral load (C_T 21.08) when diluted in water was detected in duplicate in five dilutions (1:40 to 1:640) without heat treatment, in all eight dilutions (1:5 to 1:640) following 70°C for 4 mins and in seven dilutions 1 in 5 to 1 in 640 following 98°C for 2 mins (Table 1, Panel A). When diluted in 10% (w/v) Chelex[®] 100 Resin the same saliva sample (C_T 21.08) was detected in duplicate in seven dilutions (1:10 to 1:640) without heat treatment and in all eight dilutions (1:5 to 1:640) following either 70°C for 4 minutes or 98oC for 2 minutes (Table 1, Panel A).

219

The saliva sample with a C_T of 24.47 when diluted in water was not detected in duplicate in any dilution without heat or following 70°C for 4 mins (Table 1, Panel B). This sample was detected in duplicate in three dilutions (1:5 to 1 in 20) only following 98°C for 2 mins (table 1). When diluted in 10% (w/v) Chelex® 100 Resin the same saliva sample (C_T 24.47) was detected in duplicate in one dilution (1:20) without heat treatment, in 4 dilutions (1:10 to 1:80) following 70°C for 4 minutes and in five dilutions (1:5 to 1:40 and 1: 160) following 98°C for 2 minutes (Table 1, Panel B).

226

The saliva sample with the lowest viral load ($C_T 25.27$) when diluted in water was not detected in duplicate in any dilution without heat or following 70°C for 4 mins (Table 1, Panel C). This sample was detected in duplicate in one dilution (1:5) only following 98°C for 4 mins (Table 1, Panel C). When diluted in 10% (w/v) Chelex[®] 100 Resin the same saliva sample ($C_T 25.27$) was detected in duplicate in two dilutions (1:40 and 1:80) without heat treatment, in no dilutions following 70°C for 4 minutes and
in four dilutions (1:5 to 1:40) following 98°C for 2 minutes (Table 1, Panel C).

233

The pool of saliva samples negative for SARS-CoV-2 was negative also on Direct RT-LAMP for all assay

235 conditions (data not shown as all samples reported a negative result).

236

The whole inactivate virus spiked into saliva with a C_T of 26.70 when diluted in water was detected in duplicate at one dilution (1:40) without heat, in three dilutions (1:10, 1:20, 1:40) following 70°C for 4 mins and in two dilutions (1:5 and 1:10) following 98°C for 2 mins (Table 2). When diluted in 10% (w/v) Chelex[®] 100 Resin the same saliva sample was detected in duplicate in two dilutions (1:20 and 1:40) without heat treatment, in three dilutions (1:10, 1:20, 1:40) following 70°C for 4 minutes and in all four dilutions (1:5 to 1:40) following 98°C for 2 minutes (Table 2).

243

A further dilution series of SARS-CoV-2 inactivated whole virus was prepared to include the 1:1 244 245 Mucolyse[™] dilution that is used for clinical samples and to extend beyond a 1:40 dilution to reach the 246 limit of detection of the Direct RT-LAMP assay. The whole inactivated virus spiked into saliva (C_T of 247 22.86 when diluted in water was detected in duplicate at one dilution (1:80) without heat, in three 248 dilutions (1:5, 1:10 and 1:80) following 70°C for 4 mins and in three dilutions (1:5, 1:10 and 1:40) 249 following 98°C for 2 mins (Table 3). When diluted in 10% (w/v) Chelex[®] 100 Resin the same saliva 250 sample was detected in duplicate in three dilutions (1:20, 1:40 and 1:80) without heat treatment, in six dilutions (1:5, 1:10, 1:20, 1:40, 1:80 and 1:160) following 70°C for 4 minutes and in six dilutions 251 252 (1:5, 1:10, 1:20, 1:40, 1:80, 1:160) following 98°C for 2 minutes (Table 3).

253

254 Discussion

This study describes the rapid optimization of a method to permit direct detection of SARS-CoV-2 RNA
 within saliva samples using RT-LAMP, without need for prior RNA extraction. Our previous publication

257 was focused on optimizing conditions for rapid detection of SARS-CoV-2 within viral transport media 258 from swabs samples²². In that publication, preliminary evaluation of the direct transfer of the swab 259 sample preparation method for comparable detection in paired saliva samples was poor, indicating 260 that a different sample preparation method would be required for optimal detection of SARS-CoV-2 261 RNA in crude saliva. In this study we show for the first time that the optimal sample preparation 262 method to allow SARS-CoV-2 RNA detection within crude saliva samples (1:1 mix of saliva and 263 Mucolyse[™] (active ingredient dithiothreitol)) requires saliva dilution in 10% (w/v) Chelex[®] 100 Resin 264 and heating to 98°C 2 minutes prior to adding to the direct RT-LAMP reagents.

265

266 When using this approach SARS-CoV-2 RNA was reliably detected in duplicates for a wide range of 267 dilutions assessed from positive saliva samples with a starting C_T value of 21.08, 24.47 and 25.27. The 268 combination of a chelating resin (Chelex[®] 100 Resin) and heating the sample to 98°C successfully overcame matrix inhibition and or matrix "protection" of viral capsid nucleic acid release which was 269 270 observed in the samples which did not receive this protocol. The time to positivity (speed at which 271 SARS-CoV-2 RNA was detected in saliva) was proportional to the "strength" of the saliva sample after 272 addition of 1:1 Mucolyse[™] (active ingredient: dithiothreitol) as determined by real-time reverse-273 transcriptase PCR with SARS-CoV-2 detected in 05:55 (C_T 21.08), 08:39 (C_T 24.47) and 09:15 (C_T 25.27) 274 minutes, respectively when using a dilution of 1:10 of saliva into 10% (w/v) Chelex® 100 Resin. 275 Importantly, using this method, no amplification was detected in the negative pooled saliva samples, 276 confirming the compatibility of this sample preparation approach in maintaining specificity of the 277 assay.

278

Due to the lower prevalence of SARS-CoV-2 at the time of optimisation of this sample preparation method, only three positive saliva samples were available for analysis. To strengthen conclusions drawn from these clinical specimens spiked dilution series of whole inactivated virus spiked into pooled saliva were also evaluated with equivalent results obtained. This method should therefore be

translatable to saliva samples regardless of whether they are obtained from symptomatic or asymptomatic patients.

285

Studies in macaque monkeys demonstrated that the salivary glands in the mouth are the first site in 286 the body to be affected by SARS-CoV infection²⁴ and several groups have reported high sensitivity and 287 288 specificity saliva of rRT-PCR for SARS-CoV-2 in COVID-19 patients^{25,26}. SARS-CoV-2 is therefore present 289 in saliva samples early in the course of infection and can be spread to other individuals efficiently 290 through salivary droplets generated when talking loudly or singing²⁷. Population screening of saliva 291 samples may therefore be an effective strategy to detect the important group of people who are 292 infectious but not yet symptomatic. There is also evidence that SARS-CoV-2 may be present in saliva during the recovery phase from infection after upper respiratory samples have become negative²⁸, 293 294 making saliva an attractive sample type for identification of individuals in the population who could 295 transmit infection⁴.

296

297 These findings add to the increasing literature supporting saliva as a reliable sample type in which to 298 detect SARS-Cov-2 RNA. Using saliva samples collected in a simple collection pot, we described an 299 approach that paves the way for a rapid diagnostic test for the presence of the SARS-CoV-2 virus based 300 on samples that can simply be collected at home or in other non-health care settings. Critically, this 301 approach overcomes both the requirement and validation of different swabs and the global 302 bottleneck observed in obtaining RNA extraction robots and reagents to enable molecular testing by 303 PCR. Such testing opens the possibility of public health approaches for suppression of the COVID-19 304 pandemic through regular SARS-CoV-2 testing at a population scale at relatively low cost, combined 305 with isolation and contact tracing for positive cases.

306

307

308 Ethics

309 UHS saliva collection and analysis was conducted with informed written consent following institutional
 310 review board approval (ENACT – Enabling New Approaches for CoVID-19 Treatment).

311

312 Funding

313 This work was funded by a Department of Health and Social Care award to the University of 314 Southampton (Grant Reference Number 2020/032 (Feasibility study for city-wide testing using saliva 315 based LAMP testing)). The views expressed are those of the authors and not necessarily those of the 316 Department of Health and Social Care. KMG is supported by the UK Medical Research Council 317 (MC UU 12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-318 10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)) and the British 319 Heart Foundation (RG/15/17/3174). For this project, Emma Howson was on secondment at GeneSys 320 Biotech Ltd, which was part funded by The Pirbright Institute Flexible Talent Mobility Account (FTMA) 321 under BBSRC grant BB/S507945/1. The analytical testing was conducted at HHFT and at Defra 322 maintained facilities at the Animal and Plant Health Agency-Weybridge.

324 References

- Peto Julian, Alwan Nisreen A., Godfrey Keith M., Burgess Rochelle A., Hunter David J., Riboli
 Elio, et al. Universal weekly testing as the UK COVID-19 lockdown exit strategy. *Lancet*
- 327 2020;**395**(10234):1420–1. Doi: 10.1016/S0140-6736(20)30936-3.
- 328 2 PE Sax. Rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-
- 329 vaccine. Available at https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-

330 inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-

- 331 vaccine/2020/07/05/ n.d.
- 332 3 World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in

333 suspected human cases. Available at https://www.who.int/publications/i/item/laboratory-

testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117 n.d.

- Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic
 accuracy study 2020;(January).
- Reuters. UK has fixed swab shortage problem for coronavirus testing. Available at
 https://uk.reuters.com/article/uk-health-coronavirus-britain-swabs/uk-has-fixed-swab-

339 shortage-problem-for-coronavirus-testing-minister-idUKKBN21K2SA n.d.

- Wei Shan, Kohl Esther, Djandji Alexandre, Morgan Stephanie, Whittier Susan, Mansukhani
 Mahesh, et al. Field-deployable, rapid diagnostic testing of saliva samples for SARS-CoV-2.
 MedRxiv 2020:2020.06.13.20129841. Doi: 10.1101/2020.06.13.20129841.
- 343 7 Sri Santosh Tatikonda, Parmar Reshu, Anand Hanish, Srikanth Konkati, Saritha Madham. A
 344 Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19. *Cureus*345 2020;**12**(4). Doi: 10.7759/cureus.7708.
- 346 8 Tsugunori Notomi, Okayama Hiroto, Masubuchi Harumi, Yonekawa Toshihiro, Watanabe
 347 Keiko, Amino Nobuyuki, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids*348 *Res* 2000;**28**(12):63.
- 349 9 Keikha Masoud. *LAMP Method as One of the Best Candidates for Replacing with PCR Method*.

350 vol. 25. n.d.

Howson E. L. A., Armson B., Lyons N. A., Chepkwony E., Kasanga C. J., Kandusi S., et al. Direct
detection and characterization of foot-and-mouth disease virus in East Africa using a fieldready real-time PCR platform. *Transbound Emerg Dis* 2018;65(1):221–31. Doi:
10.1111/tbed.12684.

Tsai Chi Chu, Shih Huei Chuan, Ko Ya Zhu, Wang Ren Huang, Li Shu Ju, Chiang Yu Chung. Direct
LAMP assay without prior DNA purification for sex determination of papaya. *Int J Mol Sci*2016;**17**(10). Doi: 10.3390/ijms17101630.

358 12 Mahony James, Chong Sylvia, Bulir David, Ruyter Alexandra, Mwawasi Ken, Waltho Daniel. Multiplex loop-mediated isothermal amplification (M-LAMP) assay for the detection of 359 influenza A/H1, A/H3 and influenza B can provide a specimen-to-result diagnosis in 40min with 360 361 single genome сору sensitivity. J Clin Virol 2013;58(1):127-31. Doi: 362 https://doi.org/10.1016/j.jcv.2013.06.006.

Wong Y. P., Othman S., Lau Y. L., Radu S., Chee H. Y. Loop-mediated isothermal amplification
(LAMP): a versatile technique for detection of micro-organisms. *J Appl Microbiol* 2018:626–43.
Doi: 10.1111/jam.13647.

366 14 Zhao Jiangtao, Feng Ruo. Sensitive and rapid detection of Zika virus by loop-mediated
 367 isothermal amplification. *Virus Genes* 2019;**55**(1):43–50. Doi: 10.1007/s11262-018-1612-x.

Fowler Veronica L., Howson Emma L.A., Madi Mikidache, Mioulet Valérie, Caiusi Chiara,
 Pauszek Steven J., et al. Development of a reverse transcription loop-mediated isothermal
 amplification assay for the detection of vesicular stomatitis New Jersey virus: Use of rapid
 molecular assays to differentiate between vesicular disease viruses. *J Virol Methods* 2016;**234**:123–31. Doi: 10.1016/j.jviromet.2016.04.012.

Armson Bryony, Walsh Charlotte, Morant Nick, Fowler Veronica L, Knowles Nick J., Clark
 Duncan. The development of two field-ready reverse transcription loop-mediated isothermal
 amplification assays for the rapid detection of Seneca Valley virus 1. *Transbound Emerg Dis*

376 2019;**66**(1):497–504. Doi: 10.1111/tbed.13051.

- Feng Wenzhuo, Nukaya Akira, Satou Mamoru, Fukuta Naoko, Ishiguro Yasushi, Suga Haruhisa,
 et al. Use of LAMP detection to identify potential contamination sources of plant-pathogenic
 pythium species in hydroponic culture systems of tomato and eustoma. *Plant Dis*2018;**102**(7):1357–64. Doi: 10.1094/PDIS-10-17-1679-RE.
- Feng Wenzhuo, Hieno Ayaka, Kusunoki Mikio, Suga Haruhisa, Kageyama Koji. LAMP detection
 of four plant-pathogenic oomycetes and its application in lettuce fields. *Plant Dis* 2019;103(2):298–307. Doi: 10.1094/PDIS-05-18-0858-RE.
- Tomlinson Jenny, Boonham Neil. Real-Time LAMP for Chalara fraxinea Diagnosis. *Methods Mol Biol* 2015;1302:75–83. Doi: 10.1007/978-1-4939-2620-6_6.
- Yan Chao, Cui Jinghua, Huang Lei, Du Bing, Chen Lu, Xue Guanhua, et al. Rapid and visual
 detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated
 isothermal amplification assay. *Clin Microbiol Infect* 2020. Doi: 10.1016/j.cmi.2020.04.001.
- de Paz Héctor David, Brotons Pedro, Esteva Cristina, Muñoz-Almagro Carmen. Validation of a
 Loop-Mediated Isothermal Amplification Assay for Rapid Diagnosis of Invasive Pneumococcal
- 391 Disease. Front Cell Infect Microbiol 2020;**10**. Doi: 10.3389/fcimb.2020.00115.
- 392 22 Fowler Veronica L, Armson Bryony, Gonzales Jose L, Wise Emma L, Howson Emma L A, Vincent-
- 393 Mistiaen Zoe, et al. A reverse-transcription loop-mediated isothermal amplification (RT-LAMP)
- 394 assay for the rapid detection of SARS-CoV-2 within nasopharyngeal and oropharyngeal swabs
- at Hampshire Hospitals NHS Foundation Trust Keywords. *MedRxiv* 2020:2020.06.30.20142935.
- 396 Doi: 10.1101/2020.06.30.20142935.
- Walsh P. Sean, Metzger David A., Higuchi Russell. Biotechniques 30th anniversary gem Chelex
 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. *Biotechniques* 2013;**54**(3):506–13.
- Liu L., Wei Q., Alvarez X., Wang H., Du Y., Zhu H., et al. Epithelial Cells Lining Salivary Gland
 Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the

402	Upper	Respiratory	Tracts	of	Rhesus	Macaques.	J	Virol	2011; 85 (8):4025–30.	Doi
-----	-------	-------------	--------	----	--------	-----------	---	-------	------------------------------	-----

403 10.1128/jvi.02292-10.

- 404 25 Zhu Jialou, Guo Jiubiao, Xu Yuzhong, Chen Xinchun. Viral dynamics of SARS-CoV-2 in saliva from
- 405 infected patients. *J Infect* 2020;(xxxx):10–2. Doi: 10.1016/j.jinf.2020.06.059.
- 406 26 Azzi Lorenzo, Carcano Giulio, Gianfagna Francesco, Grossi Paolo, Dalla Daniela, Genoni Angelo,
- 407 et al. Saliva is a reliable tool to detect SARS-CoV-2 2020;(January).
- 408 27 Han Pingping. Saliva Friend and Foe in the COVID-19 Outbreak 2020.
- 409 28 Azzi Lorenzo, Carcano Giulio, Dalla Gasperina Daniela, Sessa Fausto, Maurino Vittorio, Baj
- 410 Andreina. Two cases of COVID-19 with positive salivary and negative pharyngeal or respiratory
- 411 swabs at hospital discharge: a rising concern. *Oral Dis* 2020;(April):1–3. Doi:
- 412 10.1111/odi.13368.

		Panel A: AHHFT Saliva C _T 21.08 (1:1 in Mucolyse [™])							Panel B: UHS Saliva C _T 24.47 (1:1 in Mucolyse [™])					Panel C: UHS Saliva C _T 25.27 (1:1 in Mucolyse [™])								
		rRT-PCR	No	Heat	70°C 4	4 mins	98°C	2 mins	rRT-PCR	rRT-PCR No Heat		70°C	70°C 4 mins		98°C 2 mins		No Heat		70°C 4 mins		98°C 2	2 mins
Treatment	Dilution	CT	Тр	Anneal	Тр	Anneal	Тр	Anneal	CT	Тр	Anneal	Тр	Anneal	Тр	Anneal	CT	Тр	Anneal	Тр	Anneal	Тр	Anneal
Saliva in NFW	1 in5 1 in5	19.92			08:32 08:15	83.38 83.32	06:53 06:59	83.66 83.68	25.83					13:21 13:25	83.39 83.24	26.39					12:14 10:26	83.05 83.17
	1 in 10 1 in 10	19.25			08:07 07:35	83.30 83.40	07:05 06:56	83.53 83.55	26.34					14:38 13:06	83.11 83.41	27.97					11:48	83.13
	1 in 20 1 in 20	19.75	12:28	83.56	07:50 08:08	83.33 83.39	07:20 07:37	83.47 83.52	26.21	12:09	83.65			10:00 09:38	83.29 83.34	28.98						
	1 in 40 1 in 40	20.41	09:16 10:40	83.65 83.59	08:45 08:54	83.37 83.29	07:32 07:34	83.65 83.54	27.24					13:46	83.25	30.36			14:29	83.81		
	1 in 80 1 in 80	21.32	09:08 09:27	83.75 83.71	08:43 08:25	84.02 83.94	08:18 07:57	83.69 83.60	28.15							31.22			11:42	83.08		
	1 in 160 1 in 160	22.66	08:21 08:25	83.70 83.62	10:15 10:57	83.95 84.00	08:10 09:47	83.62 83.59	30.09							32.17						
	1 in 320 1 in 320	23.58	08:30 09:19	83.63 83.66	09:21 08:41	83.71 83.73	10:07 09:36	83.60 83.67	30.95							33.86	12:17	83.09				
	1 in 640 1 in 640	23.99	09:42 08:28	83.66 83.66	08:54 08:38	83.01 83.97	08:25	83.68	31.83							34.70						
	1 in5 1 in5	18.84	14:32	83.50	06:05 06:09	83.69 83.67	05:43 05:47	83.73 83.68	25.97			10:17	83.40	08:31 12:16	83.83 83.60	28.23					09:18 08:35	83.39 83.35
nise	1 in 10 1 in 10	19.22	08:51 09:47	83.58 83.56	06:07 06:07	83.54 83.56	05:54 05:56	83.70 83.65	26.34	11:21	83.27	09:24 09:32	83.30 83.31	09:02 08:17	83.36 83.31	29.96	09:29	83.13	10:22	83.22	09:37 08:53	83.32 83.32
lex [®] Rt	1 in 20 1 in 20	19.7	07:44 08:38	83.52 83.55	06:15 06:11	83.43 83.62	06:03 06:05	83.61 83.72	27.02	12:45 12:57	83.19 83.28	08:30 09:49	83.31 83.40	08:20 08:29	83.23 83.35	30.17			13:10	83.06	09:20 10:36	83.19 83.16
v) Che	1 in 40 1 in 40	21.08	08:14 07:37	83.61 83.52	06:18 06:18	83.62 83.56	06:07 06:13	83.68 83.67	28.27			12:57 08:46	83.52 83.32	07:59 14:06	83.33 83.32	31.39	12:19 12:52	83.05 83.05	08:48	83.12	09:44 10:20	83.15 83.96
/m) %	1 in 80 1 in 80	22.25	07:37 07:38	83.87 83.03	06:29 06:31	83.82 83.75	06:32 06:37	83.62 83.60	28.47			11:51 10:25	83.32 83.31	10:50	83.35	32.43	11:19 09:25	83.05 83.26	08:11	83.44		
a in 10	1 in 160 1 in 160	23.05	07:47 07:32	83.56 83.53	06:57 06:47	83.74 83.65	06:51 06:52	83.61 83.59	29.52			13:10	83:15	10:41 09:46	83.41 83.41	33.88						
Saliva	1 in 320 1 in 320	24.05	08:00 08:03	83.58 83.58	07:02 07:27	83.68 83.68	07:08 07:15	83.60 83.60	30.26					13:22	83.28	34.98						
	1 in 640 1 in 640	24.6	08:12 08:33	83.61 83.60	07:25 08:04	83.66 83.58	07:32 07:22	83.65 83.63	31.55					12:10	83.23	34.98						

Table 1. Sample preparation optimisation for direct detection of SARS-CoV-2 in crude saliva

HHFT: Hampshire Hospitals NHS Foundation Trust; UHS: University Hospital Southampton; NFW: Nuclease free water; C_T: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates. Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.

			No Heat			70°C 4 mins		98°C 2 mins				
Treatment	Dilution	rRT-PCR CT	Тр	Anneal	rRT-PCR C _T	Тр	Anneal	rRT-PCR CT	Тр	Anneal		
	1 in5 1 in5	24.19			21.37	11:57	83.25	22.04	09:40 12:37	83.53 83.33		
NFW	1 in 10 1 in 10	20.39	12:23	83.11	22.23	10:09 09:58	83.34 83.34	22.25	11:03 11:39	83.77 83.22		
aliva in	1 in 20 1 in 20	21.21	12:55	83.16	23.21	09:24 09:53	83.30 83.35	23.07	11:16	83.33		
Ss —	1 in 40 1 in 40	22.64	10:02 08:59	83.33 83.29	24.62	11:54 09:16	83.4 83.45	24.83	14:29	83.15		
(v) ri	1 in5 1 in5	23.71			21.48	11:02	83.32	22.96	08:07 07:51	83.57 83.48		
)% (w/ 00 Res	1 in 10 1 in 10	19.78	12:01	83.24	22.95	09:04 09:17	83.37 83.33	20.8	08:17 07:35	83.46 83.38		
a in 10 lex® 1(1 in 20 1 in 20	21.08	10:20 10:39	83.24 83.29	23.22	10:55 08:35	83.28 83.35	23.09	07:54 08:13	83.35 83.39		
Saliv Chel	1 in 40 1 in 40	21.85	09:16 08:47	83.32 83.28	23.92	09:21 10:08	83.3 83.27	23.89	08:48 08:04	83.62 83.54		

Table 2: Dilution series of inactivated whole virus spiked into pooled saliva from 25 negative patient samples (no predilution 1:1 in MucolyseTM)

NFW: Nuclease free water; C_T: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates. Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.

		No Heat (spiked sa	ample 1:1 in N	/lucolyse™)	70°C 4 mins (sp	iked sample 1:1	in Mucolyse™)	98°C 2 mins (spil	ked sample 1:1	in Mucolyse™)
Treatment	Dilution	rRT-PCR C _T	Тр	Anneal	rRT-PCR C _T	Тр	Anneal	rRT-PCR C _T	Тр	Anneal
	1 in5 1 in5	21.97			21.97	11:31 10:30	83.63 83.48	21.97	09:01 09:34	83.41 83.39
	1 in 10 1 in 10	22.32			22.32	13:36 10:11	83.42 83.39	22.32	09:37 11:31	83.36 83.29
	1 in 20 1 in 20	23.67			23.67	10:14	83.20	23.67	11:52	83.23
Ň	1 in 40 1 in 40	24.32	12:38	83.37	24.32	10:15	83.60	24.32	08:44 10:38	83.44 83.40
a in NF	1 in 80 1 in 80	25.3	09:55 09:06	83.58 83.44	25.3	09:30 09:42	83.35 83.35	25.3	14:58	83.37
Saliv	1 in 160 1 in 160	26.81			26.81			26.81	14:05	83.32
_	1 in 320 1 in 320	28.77			28.77			28.77		
_	1 in 640 1 in 640	29.72	10:10	83.63	29.72			29.72		
_	1 in 1280 1 in 1280	29.85			29.85			29.85		
	1 in5 1 in5	22.49			22.49	07:21 07:34	83.68 83.54	22.49	07:11 07:43	83.50 83.41
- -	1 in 10 1 in 10	23.17			23.17	07:48 08:16	83.58 83.45	23.17	10:06 08:32	83.40 83.35
00 Res	1 in 20 1 in 20	24.33	10:11 10:20	83.58 83.59	24.33	07:41 07:41	83.43 83.46	24.33	08:42 08:39	83.35 83.40
lex® 1	1 in 40 1 in 40	25.5	12:30 11:52	83.53 83.38	25.5	08:05 08:07	83.45 83.28	25.5	08:38 07:55	83.41 83.32
v) Che	1 in 80 1 in 80	26.63	07:59 09:34	83.67 83.56	26.63	10:42 09:05	83.52 83.41	26.63	10:47 10:45	83.32 83.24
/w) %(1 in 160 1 in 160	26.43	11:14	83.54	26.43	10:00 09:50	83.48 83.40	26.43	10:22 10:26	83.23 83.22
a in 10	1 in 320 1 in 320	27.31			27.31	09:35	83.55	27.31		
Saliv	1 in 640 1 in 640	28.56			28.56	09:00	83.59	28.56	09:35	83.37
-	1 in 1280 1 in 1280	29.26			29.26			29.26		

Table 3: Dilution series of inactivated whole virus spiked into pooled saliva from five negative patient samples (predilution 1:1 in Mucolyse[™])

NFW: Nuclease free water; C_T: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates. Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.